Skip to main content

Table 1 Baseline characteristics of the participants

From: Comparison of therapeutic effects of mesenchymal stem cells from umbilical cord and bone marrow in the treatment of type 1 diabetes

  Control group (n = 14) MSC-treated group (n = 14) P value
Gender (M/F) 3/11 3/11 1.000
Age (year) 17 (15, 24) 15 (10, 24) 0.299
Duration (month) 3.8 (0.6, 8.0) 1.0 (0, 3.3) 0.171
DKA/DK history (case) 12 14 0.481
BMI (kg/m2) 18.0 ± 3.3 17.3 ± 2.0 0.497
HbA1c (%) 9.1 ± 2.4 10.6 ± 3.4 0.197
Islet autoantibody (case)    1.000
 Negative 2 1  
 1 positive 4 6  
 ≥ 2 positive 8 7  
FCP (pmol/L) 247.9 ± 129.2 220.9 ± 138.5 0.599
PCP (pmol/L) 564.3 ± 334.0 677.3 ± 438.1 0.450
Insulin doses (U/kg/d) 0.47 ± 0.15 0.62 ± 0.32 0.123
  1. Data are shown as number (n), mean ± standard deviation or median (interquartile range)
  2. MSC mesenchymal stem cell, DK diabetic ketosis, DKA diabetic ketosis acidosis, BMI body mass index, HbA1c haemoglobin A1c, FCP fasting C-peptide, PCP postprandial C-peptide